[
  {
    "event_id": 1,
    "drug_id": 1,
    "brand_name": "Humira",
    "generic_name": "adalimumab",
    "branded_company": "AbbVie Inc.",
    "branded_company_ticker": "ABBV",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2024-12-15",
    "related_patent_number": "US6090382",
    "related_anda_number": null,
    "certainty_score": 92.5,
    "market_opportunity": 15200000000,
    "opportunity_tier": "BLOCKBUSTER",
    "trade_recommendation": "EXECUTE TRADE",
    "recommendation_confidence": "HIGH",
    "notes": "Multiple biosimilars already approved and launched. High certainty of continued market erosion.",
    "days_until_event": 23
  },
  {
    "event_id": 2,
    "drug_id": 2,
    "brand_name": "Stelara",
    "generic_name": "ustekinumab",
    "branded_company": "Johnson & Johnson",
    "branded_company_ticker": "JNJ",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-01-20",
    "related_patent_number": "US6902734",
    "related_anda_number": null,
    "certainty_score": 78.3,
    "market_opportunity": 8600000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "MONITOR CLOSELY",
    "recommendation_confidence": "MEDIUM",
    "notes": "Key composition patent expiring. Multiple biosimilar applications pending.",
    "days_until_event": 59
  },
  {
    "event_id": 3,
    "drug_id": 3,
    "brand_name": "Jardiance",
    "generic_name": "empagliflozin",
    "branded_company": "Eli Lilly / Boehringer",
    "branded_company_ticker": "LLY",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-02-28",
    "related_patent_number": "US8551957",
    "related_anda_number": null,
    "certainty_score": 85.2,
    "market_opportunity": 5800000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "INITIATE POSITION",
    "recommendation_confidence": "HIGH",
    "notes": "SGLT2 inhibitor with strong generic interest. First-to-file ANDA filed.",
    "days_until_event": 98
  },
  {
    "event_id": 4,
    "drug_id": 4,
    "brand_name": "Trulicity",
    "generic_name": "dulaglutide",
    "branded_company": "Eli Lilly",
    "branded_company_ticker": "LLY",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-03-15",
    "related_patent_number": "US8093206",
    "related_anda_number": null,
    "certainty_score": 72.1,
    "market_opportunity": 6500000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "MONITOR CLOSELY",
    "recommendation_confidence": "MEDIUM",
    "notes": "GLP-1 receptor agonist. Some litigation ongoing. Watch for settlement news.",
    "days_until_event": 113
  },
  {
    "event_id": 5,
    "drug_id": 5,
    "brand_name": "Xarelto",
    "generic_name": "rivaroxaban",
    "branded_company": "Johnson & Johnson / Bayer",
    "branded_company_ticker": "JNJ",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-04-10",
    "related_patent_number": "US7157456",
    "related_anda_number": null,
    "certainty_score": 88.7,
    "market_opportunity": 4200000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "EXECUTE TRADE",
    "recommendation_confidence": "HIGH",
    "notes": "Anticoagulant with clear patent cliff. Multiple ANDA approvals expected.",
    "days_until_event": 139
  },
  {
    "event_id": 6,
    "drug_id": 6,
    "brand_name": "Entresto",
    "generic_name": "sacubitril/valsartan",
    "branded_company": "Novartis",
    "branded_company_ticker": "NVS",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-04-25",
    "related_patent_number": "US8101659",
    "related_anda_number": null,
    "certainty_score": 65.4,
    "market_opportunity": 4500000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "MONITOR CLOSELY",
    "recommendation_confidence": "MEDIUM",
    "notes": "Heart failure drug. Some patent challenges pending. Medium certainty.",
    "days_until_event": 154
  },
  {
    "event_id": 7,
    "drug_id": 7,
    "brand_name": "Ozempic",
    "generic_name": "semaglutide",
    "branded_company": "Novo Nordisk",
    "branded_company_ticker": "NVO",
    "event_type": "EXCLUSIVITY_END",
    "event_date": "2025-05-30",
    "related_patent_number": "US9061025",
    "related_anda_number": null,
    "certainty_score": 45.2,
    "market_opportunity": 12000000000,
    "opportunity_tier": "BLOCKBUSTER",
    "trade_recommendation": "DO NOT TRADE",
    "recommendation_confidence": "LOW",
    "notes": "Strong patent portfolio. Litigation likely to extend protection. Wait for clarity.",
    "days_until_event": 189
  },
  {
    "event_id": 8,
    "drug_id": 8,
    "brand_name": "Eliquis",
    "generic_name": "apixaban",
    "branded_company": "Bristol-Myers Squibb / Pfizer",
    "branded_company_ticker": "BMY",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-06-15",
    "related_patent_number": "US6967208",
    "related_anda_number": null,
    "certainty_score": 82.5,
    "market_opportunity": 10800000000,
    "opportunity_tier": "BLOCKBUSTER",
    "trade_recommendation": "EXECUTE TRADE",
    "recommendation_confidence": "HIGH",
    "notes": "Major anticoagulant. Settlement agreements allow generics from 2028, but key patents expire 2025.",
    "days_until_event": 205
  },
  {
    "event_id": 9,
    "drug_id": 9,
    "brand_name": "Imbruvica",
    "generic_name": "ibrutinib",
    "branded_company": "AbbVie / Johnson & Johnson",
    "branded_company_ticker": "ABBV",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-07-20",
    "related_patent_number": "US8088782",
    "related_anda_number": null,
    "certainty_score": 68.9,
    "market_opportunity": 4100000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "MONITOR CLOSELY",
    "recommendation_confidence": "MEDIUM",
    "notes": "BTK inhibitor for blood cancers. Some method patents may extend protection.",
    "days_until_event": 240
  },
  {
    "event_id": 10,
    "drug_id": 10,
    "brand_name": "Xtandi",
    "generic_name": "enzalutamide",
    "branded_company": "Pfizer / Astellas",
    "branded_company_ticker": "PFE",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-08-10",
    "related_patent_number": "US8445507",
    "related_anda_number": null,
    "certainty_score": 76.3,
    "market_opportunity": 3200000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "MONITOR CLOSELY",
    "recommendation_confidence": "MEDIUM",
    "notes": "Prostate cancer drug. Multiple generics in development.",
    "days_until_event": 261
  },
  {
    "event_id": 11,
    "drug_id": 11,
    "brand_name": "Vyvanse",
    "generic_name": "lisdexamfetamine",
    "branded_company": "Takeda",
    "branded_company_ticker": "TAK",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-09-05",
    "related_patent_number": "US7655630",
    "related_anda_number": null,
    "certainty_score": 91.2,
    "market_opportunity": 3800000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "EXECUTE TRADE",
    "recommendation_confidence": "HIGH",
    "notes": "ADHD medication. Generic entry imminent after settlement with Teva.",
    "days_until_event": 287
  },
  {
    "event_id": 12,
    "drug_id": 12,
    "brand_name": "Pomalyst",
    "generic_name": "pomalidomide",
    "branded_company": "Bristol-Myers Squibb",
    "branded_company_ticker": "BMY",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-10-15",
    "related_patent_number": "US7855217",
    "related_anda_number": null,
    "certainty_score": 79.8,
    "market_opportunity": 2400000000,
    "opportunity_tier": "MEDIUM_VALUE",
    "trade_recommendation": "INITIATE POSITION",
    "recommendation_confidence": "HIGH",
    "notes": "Multiple myeloma drug. Clear patent cliff pathway.",
    "days_until_event": 327
  },
  {
    "event_id": 13,
    "drug_id": 13,
    "brand_name": "Opdivo",
    "generic_name": "nivolumab",
    "branded_company": "Bristol-Myers Squibb",
    "branded_company_ticker": "BMY",
    "event_type": "EXCLUSIVITY_END",
    "event_date": "2025-11-20",
    "related_patent_number": "US8728474",
    "related_anda_number": null,
    "certainty_score": 52.1,
    "market_opportunity": 7500000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "DO NOT TRADE",
    "recommendation_confidence": "LOW",
    "notes": "PD-1 inhibitor with complex patent landscape. Biosimilar timeline uncertain.",
    "days_until_event": 363
  },
  {
    "event_id": 14,
    "drug_id": 14,
    "brand_name": "Keytruda",
    "generic_name": "pembrolizumab",
    "branded_company": "Merck",
    "branded_company_ticker": "MRK",
    "event_type": "PATENT_EXPIRATION",
    "event_date": "2025-12-10",
    "related_patent_number": "US8354509",
    "related_anda_number": null,
    "certainty_score": 48.5,
    "market_opportunity": 18000000000,
    "opportunity_tier": "BLOCKBUSTER",
    "trade_recommendation": "DO NOT TRADE",
    "recommendation_confidence": "LOW",
    "notes": "Top-selling drug. Strong patent portfolio extends to 2028. Initial patents less critical.",
    "days_until_event": 383
  },
  {
    "event_id": 15,
    "drug_id": 15,
    "brand_name": "Revlimid",
    "generic_name": "lenalidomide",
    "branded_company": "Bristol-Myers Squibb",
    "branded_company_ticker": "BMY",
    "event_type": "EXCLUSIVITY_END",
    "event_date": "2025-12-28",
    "related_patent_number": "US5635517",
    "related_anda_number": null,
    "certainty_score": 95.8,
    "market_opportunity": 4200000000,
    "opportunity_tier": "HIGH_VALUE",
    "trade_recommendation": "EXECUTE TRADE",
    "recommendation_confidence": "HIGH",
    "notes": "Final settlement allows full generic competition. Market erosion accelerating.",
    "days_until_event": 401
  }
]
